Sonogen Medical, Inc.
Sonogen is working to commercialize a next-generation ultrasonic bone growth stimulation device proven to be 30% more effective in initial POC testing.
Sonogen has developed an ultrasonic bone fracture diagnostics and healing device that heals 30% faster than the current standard of care. Our device will save patients $1B/year in lost wages, and payors $12B/year in avoided surgeries. This is a $3.6B total available market; we are 12 months from FDA submission. We have a lead investor and are looking for firms to syndicate; investors receive a 50% biotech investment rebate from the state of MD.